Rivoceranib
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Ruijin HospitalSmall moleculePhase 4 / ApprovedActive
BBB
72/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 57/ 100
- Competitive Position
- 95/ 100
Competitive context
127 Active assets in the Peripheral T-Cell Lymphoma, Not Otherwise Specified cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Adriamycin BeBetter Med Inc | Phase 4 | BBB |
Pralatrexate Peking University People's Hospital | Phase 4 | BBB |
Prednisone Tarapeutics Science Inc. | Phase 4 | BBB |
Cyclophosphamide Tarapeutics Science Inc. | Phase 4 | BBB |
(+)-VINCRISTINE BeBetter Med Inc | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Rivoceranib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →